Researchers develop blood test to gauge Alzheimer's risk

 01 Feb 2018 - 11:18

Researchers develop blood test to gauge Alzheimer's risk
Image used for representation.

Reuters

TOKYO/MELBOURNE: Researchers in Japan and Australia have developed a blood test that detects the toxic protein amyloid beta which has been linked to Alzheimer's brain disease.

The joint study published in the scientific journal Nature on Wednesday said the test was more than 90 percent accurate.

The study was based on 252 Australian and 121 Japanese patients aged 60 to 90 years of age, some classed as cognitively normal, others with mild cognitive impairment and some with Alzheimer's.

The blood test opens the way for possibly far cheaper and less invasive tests for amyloid beta, which builds up in the brain as Alzheimer's develops, said the researchers.

Currently brain scans or invasive cerebrospinal fluid testing, also known as a spinal tap, are used to ascertain the deposition in the brain of an abnormal protein, called amyloid beta. Some brain imaging tests can cost more than 150,000 yen ($915).

A simple, low-cost blood tests could also make it easier for pharmaceutical companies to secure enough people at risk of Alzheimer's to test new drugs to fight the disease, said researchers.

"Our blood test may ... have a transformative potential to facilitate the development of effective drugs for Alzheimer's disease," Katsuhiko Yanagisawa, director-general of the Japanese National Center for Geriatrics and Gerontology's research institute, said in a statement.

University of Melbourne Professor Colin Masters, a member of the Australian team of researchers, said the blood test was a step towards a potential cure for the disease.

"You have got to walk before you run. You have to learn to diagnose the disease directly before you can hope to see the effect of therapeutic intervention. And that's where the real value in this test will come," Masters said.

Alzheimer's disease starts years before patients have any symptoms of memory loss, so the key to treatment is in early detection.

Alzheimer’s disease is the most common form of dementia, affecting up to 70 percent of all people with dementia, with three in 10 people over 85 having dementia, according to the Australian government's Dementia Australia organisation.

The disease was first recorded in 1907 by Dr Alois Alzheimer. ($1 = 109.3400 yen)

Related News

arrow Read More
How Sanofi’s setback could lead to better dengue vaccines

 29 Jan 2018 - 22:02

New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U.S. government scientists are poised to provide a safer alternative to Sanofi’s Dengvaxia, according to vaccine experts, because they already take into account some of the issues that sidelined the product last year.

arrow Read More
Scientists warns heavy social media users live on less

 29 Jan 2018 - 12:11

Research staff at Stanford University have conducted a number of studies and concluded that heavy users of social networks live on 10% less than other people.